| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 16 | 2025 | 152 | 4.070 |
Why?
|
| Myasthenia Gravis | 8 | 2022 | 83 | 3.050 |
Why?
|
| Amyloid Neuropathies, Familial | 4 | 2022 | 44 | 2.270 |
Why?
|
| Muscle, Skeletal | 6 | 2025 | 473 | 1.620 |
Why?
|
| Electromyography | 7 | 2025 | 198 | 1.450 |
Why?
|
| Cardiomyopathies | 2 | 2022 | 300 | 1.150 |
Why?
|
| Polyneuropathies | 2 | 2023 | 26 | 1.100 |
Why?
|
| Thymectomy | 3 | 2022 | 32 | 1.010 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2017 | 90 | 0.990 |
Why?
|
| Thymoma | 3 | 2020 | 31 | 0.880 |
Why?
|
| Leg | 1 | 2025 | 139 | 0.880 |
Why?
|
| Thymus Neoplasms | 3 | 2020 | 46 | 0.870 |
Why?
|
| Machado-Joseph Disease | 1 | 2023 | 8 | 0.790 |
Why?
|
| Biomarkers | 3 | 2025 | 1905 | 0.780 |
Why?
|
| Diabetic Neuropathies | 1 | 2023 | 42 | 0.780 |
Why?
|
| Motor Neuron Disease | 3 | 2025 | 20 | 0.770 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 67 | 0.740 |
Why?
|
| Steroids | 2 | 2022 | 166 | 0.730 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.720 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2023 | 88 | 0.720 |
Why?
|
| Compartment Syndromes | 1 | 2021 | 17 | 0.670 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2023 | 247 | 0.670 |
Why?
|
| Rhabdomyolysis | 1 | 2021 | 28 | 0.670 |
Why?
|
| Low Back Pain | 1 | 2021 | 58 | 0.640 |
Why?
|
| Humans | 55 | 2025 | 93138 | 0.630 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2020 | 64 | 0.620 |
Why?
|
| Aged | 24 | 2025 | 20398 | 0.610 |
Why?
|
| Male | 36 | 2025 | 44360 | 0.600 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 98 | 0.600 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 17 | 0.590 |
Why?
|
| Facial Paralysis | 1 | 2019 | 23 | 0.580 |
Why?
|
| Facial Nerve | 1 | 2019 | 32 | 0.570 |
Why?
|
| Middle Aged | 27 | 2025 | 27539 | 0.560 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 260 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2023 | 590 | 0.540 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 168 | 0.530 |
Why?
|
| Late Onset Disorders | 1 | 2017 | 4 | 0.510 |
Why?
|
| Head Movements | 1 | 2017 | 41 | 0.500 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 202 | 0.500 |
Why?
|
| Spinal Stenosis | 1 | 2017 | 50 | 0.490 |
Why?
|
| Vital Capacity | 1 | 2016 | 71 | 0.490 |
Why?
|
| Gastrostomy | 1 | 2016 | 66 | 0.480 |
Why?
|
| Enteral Nutrition | 1 | 2016 | 104 | 0.480 |
Why?
|
| Hepatitis C | 1 | 2017 | 181 | 0.450 |
Why?
|
| Female | 29 | 2025 | 48547 | 0.440 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 376 | 0.440 |
Why?
|
| Pneumothorax | 1 | 2015 | 51 | 0.440 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1193 | 0.430 |
Why?
|
| Melanoma | 1 | 2019 | 494 | 0.430 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 111 | 0.420 |
Why?
|
| Respiration Disorders | 1 | 2014 | 42 | 0.420 |
Why?
|
| Diaphragm | 1 | 2014 | 75 | 0.410 |
Why?
|
| Spinal Curvatures | 1 | 2013 | 8 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1385 | 0.390 |
Why?
|
| Immunotherapy | 1 | 2019 | 762 | 0.390 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 578 | 0.380 |
Why?
|
| Muscular Diseases | 1 | 2013 | 64 | 0.380 |
Why?
|
| Prealbumin | 2 | 2022 | 45 | 0.360 |
Why?
|
| Spinal Cord Diseases | 1 | 2013 | 88 | 0.360 |
Why?
|
| Neuromuscular Diseases | 1 | 2012 | 25 | 0.350 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 257 | 0.350 |
Why?
|
| Spinal Cord | 1 | 2013 | 236 | 0.340 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2011 | 104 | 0.340 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 100 | 0.310 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1171 | 0.310 |
Why?
|
| Postoperative Complications | 2 | 2022 | 2552 | 0.310 |
Why?
|
| Lymphoma | 1 | 2011 | 247 | 0.310 |
Why?
|
| Diagnosis, Differential | 6 | 2024 | 1519 | 0.300 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 122 | 0.300 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 199 | 0.300 |
Why?
|
| Adult | 16 | 2025 | 27850 | 0.290 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 188 | 0.280 |
Why?
|
| Pain | 1 | 2011 | 412 | 0.270 |
Why?
|
| Insulin | 2 | 2023 | 1184 | 0.270 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 600 | 0.270 |
Why?
|
| Pyridostigmine Bromide | 3 | 2020 | 12 | 0.270 |
Why?
|
| Tarlov Cysts | 1 | 2006 | 2 | 0.250 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2 | 2004 | 10 | 0.250 |
Why?
|
| Depression | 1 | 2011 | 540 | 0.250 |
Why?
|
| Mutation | 3 | 2022 | 4265 | 0.240 |
Why?
|
| Central Nervous System Diseases | 1 | 2006 | 36 | 0.240 |
Why?
|
| Demyelinating Diseases | 1 | 2006 | 48 | 0.240 |
Why?
|
| Prednisone | 2 | 2020 | 242 | 0.240 |
Why?
|
| Prospective Studies | 3 | 2024 | 4546 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 1000 | 0.220 |
Why?
|
| Isometric Contraction | 2 | 2024 | 34 | 0.220 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2025 | 16 | 0.220 |
Why?
|
| Macroglossia | 1 | 2024 | 7 | 0.220 |
Why?
|
| Treatment Outcome | 8 | 2025 | 9074 | 0.210 |
Why?
|
| Neural Conduction | 2 | 2023 | 71 | 0.210 |
Why?
|
| Ceftriaxone | 2 | 2014 | 9 | 0.200 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 1060 | 0.200 |
Why?
|
| Remission Induction | 2 | 2019 | 737 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 181 | 0.200 |
Why?
|
| Immunity, Cellular | 2 | 2020 | 183 | 0.200 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 2 | 2015 | 9 | 0.200 |
Why?
|
| Penetrance | 1 | 2003 | 49 | 0.200 |
Why?
|
| Ophthalmoplegia, Chronic Progressive External | 1 | 2023 | 3 | 0.200 |
Why?
|
| Bell Palsy | 1 | 2023 | 6 | 0.200 |
Why?
|
| Double-Blind Method | 7 | 2025 | 1727 | 0.190 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 8 | 0.190 |
Why?
|
| Technetium | 1 | 2022 | 21 | 0.190 |
Why?
|
| Diphosphates | 1 | 2022 | 15 | 0.190 |
Why?
|
| Superoxide Dismutase | 1 | 2003 | 155 | 0.190 |
Why?
|
| Motor Neurons | 1 | 2024 | 176 | 0.190 |
Why?
|
| Recurrence | 2 | 2019 | 1188 | 0.190 |
Why?
|
| Retrospective Studies | 4 | 2022 | 10132 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 3450 | 0.190 |
Why?
|
| Age of Onset | 1 | 2003 | 341 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 7039 | 0.180 |
Why?
|
| Muscle Weakness | 2 | 2017 | 67 | 0.180 |
Why?
|
| Immunologic Factors | 2 | 2020 | 175 | 0.180 |
Why?
|
| Enzyme Inhibitors | 1 | 2025 | 638 | 0.180 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2020 | 45 | 0.180 |
Why?
|
| Cerebellum | 1 | 2023 | 247 | 0.170 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2021 | 29 | 0.170 |
Why?
|
| Arm | 2 | 2024 | 96 | 0.170 |
Why?
|
| Paraspinal Muscles | 1 | 2021 | 5 | 0.170 |
Why?
|
| Lumbosacral Region | 1 | 2021 | 57 | 0.170 |
Why?
|
| Sulfonamides | 1 | 2023 | 331 | 0.160 |
Why?
|
| Meningitis | 1 | 2020 | 22 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2006 | 2479 | 0.160 |
Why?
|
| Jews | 1 | 2020 | 42 | 0.160 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 29 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1098 | 0.160 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 123 | 0.150 |
Why?
|
| Iodine Radioisotopes | 1 | 2020 | 137 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 100 | 0.150 |
Why?
|
| Thyroidectomy | 1 | 2020 | 173 | 0.150 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 184 | 0.150 |
Why?
|
| Heterozygote | 1 | 2020 | 381 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 163 | 0.150 |
Why?
|
| Ipilimumab | 1 | 2019 | 64 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 165 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 277 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 365 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 833 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2020 | 360 | 0.130 |
Why?
|
| Cryoglobulinemia | 1 | 2017 | 5 | 0.130 |
Why?
|
| Sural Nerve | 1 | 2017 | 17 | 0.130 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 355 | 0.130 |
Why?
|
| Vasculitis | 1 | 2017 | 40 | 0.130 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2017 | 19 | 0.130 |
Why?
|
| Cervical Cord | 1 | 2017 | 15 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 305 | 0.130 |
Why?
|
| Visual Analog Scale | 1 | 2016 | 18 | 0.130 |
Why?
|
| Biopsy | 1 | 2020 | 1172 | 0.120 |
Why?
|
| Gout | 1 | 2017 | 75 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2543 | 0.120 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2016 | 8 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 537 | 0.120 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 441 | 0.110 |
Why?
|
| Electroencephalography | 1 | 2020 | 798 | 0.110 |
Why?
|
| Plasmapheresis | 1 | 2015 | 26 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 810 | 0.110 |
Why?
|
| Stroke | 1 | 2023 | 1073 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 940 | 0.100 |
Why?
|
| Migraine without Aura | 1 | 2013 | 1 | 0.100 |
Why?
|
| Sumatriptan | 1 | 2013 | 2 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1518 | 0.100 |
Why?
|
| Myokymia | 1 | 2013 | 4 | 0.100 |
Why?
|
| Metoclopramide | 1 | 2013 | 12 | 0.100 |
Why?
|
| Valproic Acid | 1 | 2013 | 25 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1160 | 0.100 |
Why?
|
| Neuralgia | 1 | 2013 | 27 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 795 | 0.090 |
Why?
|
| Age Factors | 1 | 2017 | 1898 | 0.090 |
Why?
|
| Cytokines | 1 | 2016 | 862 | 0.090 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 30 | 0.090 |
Why?
|
| 2-Chloroadenosine | 1 | 2011 | 4 | 0.090 |
Why?
|
| Blindness | 1 | 2012 | 39 | 0.090 |
Why?
|
| Analgesics | 1 | 2013 | 127 | 0.090 |
Why?
|
| Coma | 1 | 2012 | 44 | 0.090 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2011 | 11 | 0.090 |
Why?
|
| Deoxyadenosines | 1 | 2011 | 23 | 0.090 |
Why?
|
| Video Recording | 1 | 2013 | 210 | 0.090 |
Why?
|
| Status Epilepticus | 1 | 2012 | 43 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 78 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 748 | 0.090 |
Why?
|
| Dyspnea | 1 | 2012 | 86 | 0.080 |
Why?
|
| Rituximab | 1 | 2011 | 129 | 0.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2011 | 73 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2011 | 292 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 278 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2011 | 240 | 0.080 |
Why?
|
| Prognosis | 2 | 2020 | 3891 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2017 | 3044 | 0.080 |
Why?
|
| Ubiquinone | 1 | 2009 | 10 | 0.080 |
Why?
|
| Research Design | 1 | 2013 | 620 | 0.070 |
Why?
|
| Aphasia | 1 | 1989 | 16 | 0.070 |
Why?
|
| Terbutaline | 1 | 2008 | 15 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2019 | 3497 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2008 | 69 | 0.070 |
Why?
|
| Feedback | 1 | 1989 | 129 | 0.070 |
Why?
|
| Antioxidants | 1 | 2009 | 231 | 0.070 |
Why?
|
| Adolescent | 5 | 2020 | 9550 | 0.060 |
Why?
|
| Hypesthesia | 1 | 2006 | 14 | 0.060 |
Why?
|
| Neurologic Examination | 1 | 2006 | 118 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3155 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2025 | 913 | 0.060 |
Why?
|
| Young Adult | 4 | 2024 | 6922 | 0.060 |
Why?
|
| Communication | 1 | 1989 | 433 | 0.060 |
Why?
|
| Creatine | 1 | 2004 | 25 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2024 | 71 | 0.050 |
Why?
|
| Weight-Bearing | 1 | 2024 | 69 | 0.050 |
Why?
|
| Valine | 1 | 2003 | 46 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2020 | 2827 | 0.050 |
Why?
|
| Alanine | 1 | 2003 | 82 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2004 | 169 | 0.050 |
Why?
|
| Family Health | 1 | 2003 | 154 | 0.050 |
Why?
|
| Potassium Channels, Voltage-Gated | 2 | 2015 | 111 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 753 | 0.050 |
Why?
|
| Spinal Nerve Roots | 1 | 2002 | 20 | 0.050 |
Why?
|
| Neurofibromatoses | 1 | 2002 | 13 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 103 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 543 | 0.040 |
Why?
|
| Exons | 1 | 2003 | 447 | 0.040 |
Why?
|
| Telemedicine | 1 | 2025 | 223 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 885 | 0.040 |
Why?
|
| Pedigree | 1 | 2003 | 962 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 78 | 0.040 |
Why?
|
| Disease Progression | 1 | 2025 | 1529 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2020 | 38 | 0.040 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Brain Stem | 1 | 2020 | 163 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 208 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 753 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 289 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 2562 | 0.030 |
Why?
|
| Receptors, Cholinergic | 1 | 2016 | 75 | 0.030 |
Why?
|
| Animals | 2 | 2006 | 27973 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1910 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 2485 | 0.030 |
Why?
|
| Isaacs Syndrome | 1 | 2015 | 2 | 0.030 |
Why?
|
| Syringomyelia | 1 | 2015 | 14 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 710 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 89 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3815 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 287 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 400 | 0.020 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2013 | 4 | 0.020 |
Why?
|
| GABA Agents | 1 | 2013 | 8 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 63 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 2013 | 33 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 212 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 131 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 190 | 0.020 |
Why?
|
| Emergencies | 1 | 2012 | 120 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2013 | 373 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 346 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 838 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 165 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 308 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 205 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2009 | 120 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 389 | 0.020 |
Why?
|
| Cognition | 1 | 1989 | 625 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 987 | 0.010 |
Why?
|
| Paraparesis | 1 | 2002 | 4 | 0.010 |
Why?
|
| Hypertrophy | 1 | 2002 | 65 | 0.010 |
Why?
|
| Radiculopathy | 1 | 2002 | 39 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 750 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 5380 | 0.010 |
Why?
|